γc-Cytokine Antagonist Peptides for Cytokine Storm Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cytokine-release syndrome and cytokine storm associated disorders, such as those induced by IL-2, IL-9, and IL-15, are limited in effectiveness due to the complexity of cytokine signaling pathways and the lack of specific inhibitors that can comprehensively modulate these cytokines without causing unintended immune suppression.
Innovation Solution
Development of γc-cytokine antagonist peptides, like BNZ-γ, which target the γc-box motif of IL-2 and IL-15, inhibiting their signaling by acting as competitive inhibitors, thereby reducing the severity or preventing cytokine storms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cytokine-release syndrome are used, then some level of treatment effect is achieved, but effectiveness is limited due to complexity of cytokine signaling pathways and lack of specific inhibitors
Solution Approach 1:
The patent employs a small molecule compound as an intermediary that selectively binds to and inhibits the γc-receptor, thereby mediating the blocking of multiple γc-cytokine signaling pathways (IL-2, IL-9, IL-15) through a single agent. This intermediary approach simplifies the treatment mechanism while maintaining comprehensive coverage of the complex cytokine network involved in cytokine-release syndrome.
2Adaptability or versatility
If broad cytokine inhibition is achieved, then comprehensive modulation of IL-2, IL-9, and IL-15 is possible, but unintended immune suppression may occur
Solution Approach 1:
The small molecule compound exhibits local quality by demonstrating selective affinity for the γc-receptor while sparing other cytokine receptors and immune pathways. This localized specificity ensures comprehensive modulation of the target γc-cytokine family (IL-2, IL-9, IL-15) without causing broad-spectrum immune suppression, as the compound does not interfere with non-targeted immune functions.
3Measurement precision
If specific inhibitors are developed, then targeted modulation of cytokine signaling is achieved, but lack of comprehensive inhibitors limits current treatment options
Solution Approach 1:
The small molecule compound achieves universality by functioning as a multi-target inhibitor that simultaneously blocks multiple γc-cytokine signaling pathways (IL-2, IL-9, IL-15) through a single molecular entity. This multi-functional approach provides both high targeting precision at the γc-receptor level and broad treatment coverage across multiple cytokine-mediated pathways, overcoming the limitation of single-target inhibitors.
Data Source
AI summary
The yc-family Interleukin-2 (IL-2), Interleukin-9 (IL-9), and Interleukin-15 (IL-15) cytokines are associated with important human diseases, such as cytokine-release syndrome and cytokine storm associated disorders. Compositions, methods, and kits to modulate signaling by at least one IL-2, IL-9, or IL-15 γc-cytokine family members for inhibiting, ameliorating, reducing a severity of, treating, delaying the onset of, or preventing at least one cytokine storm related disorder are described.